Surgery Partners (SGRY)

Healthcare · Medical Care Facilities
$13.89 +1.83% on the day Market cap $1.7B 52-week range $11.41 to $23.44 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
-6% a year for 10 years

At a market value of $1.7B, Surgery Partners's free cash flow of $196M (fiscal 2025) would need to grow about -6% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 10 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Surgery Partners's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price-5.8% a year
Free cash flow, last 10 years14.4% a year
Revenue, same period13.2% a year
Price to free cash flow8.9x

Fundamental grade

D

Five factors scored 1 to 9 from SGRY's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation7
Profitability1
Growth3
Financial health3
Cash efficiency4

Results from SEC filings

Fiscal years, from Surgery Partners's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$2.2B$2.5B$2.7B$3.1B$3.3B
Net income-$71M-$55M-$12M-$168M-$78M
Free cash flow$30M$78M$205M$210M$196M
EPS (diluted)-$1.12-$0.59-$0.09-$1.33-$0.61
Operating margin13.6%13.6%12.0%11.2%11.8%

Where the revenue comes from

Revenue by segments, fiscal 2023. Every breakdown, year by year.

Surgical Facility Services$2.7B98%
Ancillary Services$68M2%

Superinvestors who own SGRY

From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Hersh Cohen
ClearBridge Investments
Trimmed $64M0.05%Q2 2026
Howard Marks
Oaktree Capital Management
New position $14M0.26%Q2 2026
Cliff Asness
AQR Capital Management
Added $775,4040.0%Q2 2026

Insider buying

Open-market purchases by Surgery Partners's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of SGRY in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when SGRY trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Surgery Partners's stock price imply?

At a market value of $1.7B, Surgery Partners would need its free cash flow to grow about -6% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 10 years its free cash flow grew 14% a year.

Are Surgery Partners insiders buying the stock?

No open-market insider purchases of SGRY in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Surgery Partners?

3 of the superinvestors Investingly tracks hold SGRY in their latest 13F, including Hersh Cohen, Howard Marks, Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.